Different effects of octreotide by continuous night infusion at increasing rate or by evening injections at different times on morning hyperglycemia and growth hormone levels in insulin-dependent diabetic patients
- 28 Downloads
The effect of octreotide on morning hyperglycemia and GH levels was evaluated in eight insulin-dependent diabetic patients. Octreotide (50 mcg) was administered through subcutaneous injections at different hours (20: 00, 22: 00 and 24: 00h) or through continuous subcutaneous night infusion from midnight to 08: 00 at increasing rate between 03: 00 and 08: 00h. After octreotide injection at midnight we noticed a sharp decrease of both glycemia (p<0.005) and GH (p<0.05) at 04: 00h, but not at 08: 00h. Only the night continuous infusion at increasing rate was able to reduce glycemia and GH at 04: 00 and at 08: 00h (p<0.001 and p<0.01 respectively). The injections of octreotide at 20: 00 and 22: 00h lowered GH values at 24: 00h (p<0.01 and p<0.05 vs insulin alone) but did not show any signicant effect on blood glucose levels and GH at 04: 00 and 08: 00h. In conclusion, only the continuous subcutaneous night infusion of octreotide at increasing rate during the last hours of the night was able to reduce simultaneously morning hyperglycemia and GH levels in insulin-dependent diabetic patients, whereas evening subcutaneous injections at different times did not show any appreciable effect.
Key-wordsOctreotide insulin-dependent diabetes growth hormone dawn phenomenon
Unable to display preview. Download preview PDF.
- 4.Atiea J.A., Creagh F., Page M., Owens D.R., Scanlon M.F., Peter J.R. Eearly morning hyperglycaemia in insulin dependent diabetes: acute and sustained effects of cholinergic blockade. J. Clin. Endocrinol. Metab. 69: 390, 199.Google Scholar
- 13.Hyer S.L., Sharp P.S., Brooks R.A., Burrin J.M., Kohner E.M. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. Acta Endocrinol. (Copenh.) 120: 187, 1989.Google Scholar
- 16.Aarsen R.S.R., Bruining G.J., Grose W.F.A., Van Strik R., Lamberts S.W.J., Harris A. Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers. Acta Endocrinol. 116(Suppl. 28): 645, 1987.Google Scholar
- 17.Willms B., Harris A., Mehmke B. Effect if a single nocturnal administration of a long acting somatostatin analog, SMS 201–995 on blood glucose profile during the night, human growth hormone and Cortisol secretion in type 1 (insulin-dependent) diabetic patients. Diabetologia 30: 597 A, 1987.Google Scholar
- 21.Borissova A.M., Kozlowski P., Popova J., Kirilov G. Morning peripheral insulin effectiveness and night changes in growth hormone, blood glucose and basal insulin needs in patients with type 1 diabetes mellitus. Diabetes Metab. 18: 463, 1992.Google Scholar
- 22.Perriello G., De Feo P., Torlone E., Fanelli C., Santeusanio F., Brunetti P., Bolli G.B. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 diabetes mellitus by decreasing hepatic (extraepatic) sensitivity to insulin in absence of insulin waning. Diabetologia 33: 52, 1190.CrossRefGoogle Scholar
- 24.Del Pozo E., Kutz K. Pharmacological properties and effect on glucose homeostasis of a somatostatin derivative (SMS 201–995): studies in humans. In: Ludecke, Tolis, (Eds.), Growth factors and acromegaly. Reaven Press, New York, 1987, p. 207.Google Scholar